The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer

Vanuytsel, L.; Vansteenkiste, Johan; Stroobants, Sigrid; Leyn, Paul R. De; Wever, Walter De; Verbeken, Eric; Gatti, Giovanna G; Huyskens, D.; Kutcher, Gerald J.

doi:10.1016/s0167-8140(00)00138-9

Cited by 270 publications

(124 citation statements)

References 17 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…FDG-PET scans are gaining an increasing role in NSCLC for initial staging, radiation therapy planning, and restaging after therapy [11][12][13]. Furthermore, EGFR-mutant cancers preferentially activate Akt signaling [14], which in turn regulates glycolysis, glucose metabolism, and FDG avidity [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Mak¹,

Digumarthy

Muzikansky

et al. 2011

The Oncologist

View full text Add to dashboard Cite

Purpose. To compare 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) imaging characteristics in non-small cell lung cancer (NSCLC) with or without epidermal growth factor receptor (EGFR) mutations.Methods. We retrospectively identified NSCLC patients who underwent EGFR mutation testing and pretreatment FDG-PET and CT scans. The maximum standard uptake value (SUV max ) of the primary tumor and any metastases was measured and normalized to the SUV of blood in the pulmonary artery. We compared normalized SUV max values between EGFRmutant and wild-type patients and modeled radiographic and clinical predictors of EGFR mutation status. Receiver operator characteristic (ROC) curves were used to identify potential SUV cutoffs predictive of genotype. Results.We included 100 patients (24 EGFRmutant and 76 wild-type). There was a trend for higher normalized SUV max in the primary tumors among patients with EGFR-wild-type versus mutant (median, 3.4; range, 0.6 -12.8; versus median, 2.9; range, 0.4 -5.0; p ‫؍‬ .09). Normalized SUV max of nodal and distant metastases, and CT characteristics were not associated with genotype. On multivariate analysis, low normalized SUV max of the primary tumor was predictive for EGFR mutation (odds ratio, 0.72; 95% confidence interval, 0.53-0.98; p ‫؍‬ .034). ROC curve analyses yielded an area under the curve of 0.62, and identified a potential cutoff of >5.0 to distinguish wild-type from mutant tumors.Conclusions. In this retrospective study, high FDG avidity (normalized SUV max >5) correlated with EGFR-wild-type genotype. Although genotyping reCorrespondence: Lecia V. Sequist, M.D., M.P.H.,

show abstract

Section: Introductionmentioning

confidence: 99%

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Mak¹,

Digumarthy

Muzikansky

et al. 2011

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Previously reported small studies have shown that FDG-PET/CT modifies the GTV defined by CT [11,[14][15][16][17][18][19][20][21][22][23][24]. Most of these studies determined only the interobserver variability of target volumes for changes in size, not position and overlap.…”

Section: Discussionmentioning

confidence: 99%

A Prospective Study to Determine Inter-observer Variability of Gross Tumor Volume with [18F] Fludeoxyglucose-PET/CT Compared to CT Alone in Stage III Non-Small Cell Lung Cancer Using Three-Dimensional Analysis

Peterson¹,

Ahmed²,

Rivest³

et al. 2013

Cureus

View full text Add to dashboard Cite

“…

PET/CT : Studies have demonstrated that staging detection with FDG PET leads to improved patient management and often impacts radiation therapy planning in non‐small cell lung carcinoma (NSCLC) patients. ( 34 , 35 ) Combining functional PET and anatomical CT information presents many challenges, but a number of them have been addressed with the advent of combined PET/CT scanners. ( 36 ) In a single imaging study, these systems consecutively acquire CT and PET images with the patient in a fixed position on a single imaging couch in a timeframe on the order of minutes.

…”

Section: Methodsmentioning

confidence: 99%

Assessment of a commercially available automatic deformable registration system

Fallone

Rivest

Riauka

et al. 2010

J Applied Clin Med Phys

View full text Add to dashboard Cite

In recent years, a number of approaches have been applied to the problem of deformable registration validation. However, the challenge of assessing a commercial deformable registration system – in particular, an automatic registration system in which the deformable transformation is not readily accessible – has not been addressed. Using a collection of novel and established methods, we have developed a comprehensive, four‐component protocol for the validation of automatic deformable image registration systems over a range of IGRT applications. The protocol, which was applied to the Reveal‐MVS system, initially consists of a phantom study for determination of the system's general tendencies, while relative comparison of different registration settings is achieved through postregistration similarity measure evaluation. Synthetic transformations and contour‐based metrics are used for absolute verification of the system's intra‐modality and inter‐modality capabilities, respectively. Results suggest that the commercial system is more apt to account for global deformations than local variations when performing deformable image registration. Although the protocol was used to assess the capabilities of the Reveal‐MVS system, it can readily be applied to other commercial systems. The protocol is by no means static or definitive, and can be further expanded to investigate other potential deformable registration applications.PACS numbers: 87.19.xj, 87.56.Da, 87.57.nj

show abstract

The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer

Cited by 270 publications

References 17 publications

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

A Prospective Study to Determine Inter-observer Variability of Gross Tumor Volume with [18F] Fludeoxyglucose-PET/CT Compared to CT Alone in Stage III Non-Small Cell Lung Cancer Using Three-Dimensional Analysis

Assessment of a commercially available automatic deformable registration system

Contact Info

Product

Resources

About